Keywords: USA, FDA, Astham drugs, GlaxoSmithKline, AstraZeneca, Novartis, Merck & Co, Advair, Serevent, Symbicort, Foradil, LABA

US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential

Article | 19 February 2010

Print This

The US Food and Drug Administration announced yesterday that drugs in the class of long-acting beta agonists (LABAs) should never ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in